Case Study

Lonza’s mission impossible: Supplying the world with mRNA vaccines

18 pages
June 2023
Reference: IMD-7-2429

At the beginning of 2020, a few weeks before COVID-19 was declared a global pandemic, André Goerke, the Head of Value Chain Management at Lonza – a leading pharmaceutical contract development and manufacturing company based in Switzerland – had just completed the merger of two global business units into a new biotech business unit of the company. After returning from a wonderful day of snowboarding, André received a phone call from his friend Juan Andres that would change his professional focus for the next two years. Juan had become the Head of Technical Operations at the US biotech start-up Moderna – which was working on various early-stage drugs using the novel mRNA technology. The world had been watching with sorrow as cases of COVID-19 appeared in Europe, and stock markets across the globe were in free fall. After learning of these mounting concerns about a pandemic, Moderna had immediately started sequencing the COVID-19 virus. It was convinced that it had an effective and safe mRNA sequence that could serve as a vaccine against the virus. But it had not been able to manufacture anywhere near the volume necessary to fight a global pandemic. Hence, Juan asked André if Lonza could set up a global supply chain and be Moderna’s active ingredient partner to manufacture hundreds of millions of mRNA vaccine doses a year. André sensed that this was an incredible opportunity, but there were several risks involved, including counterparty, technology, legal, regulatory, supply chain and HR risks. From multiple angles, this looked like a mission impossible for Lonza, especially since manufacturing was expected to start by the end of 2020.

Learning Objective
  • How to make far-reaching strategic decisions with imperfect information at hand.
  • Lessons on organizational design, customer centricity and the adaptive strategy approach.
  • The importance of leadership with purpose and corporate culture in steering companies through phases of disruptive transformation.
Keywords
Disruption, General Management, Global Business, Strategy, Leadership, COVID-19, Vaccine, Messenger Ribonucleic Acid, Innovation, Healthcare
Settings
World/global
Lonza Group, Manufacturing, Biotechnology, Healthcare, Healthcare, Pharmaceuticals
2020-2022
Type
Field Research
Copyright
© 2023
Available Languages
English
Related material
Teaching note
Case clearing houses
IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.

The Case Centre

Cranfield University

Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]

Harvard Business School Publishing

60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]

Asia Pacific Case Center

NUCB Business School

1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Discover our latest research
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics